Mild cognitive impairment
Conditions
Interventions
tDCS+iTBS:Cathodal tDCS premodulates iTBS
Sham tDCS+ sham iTBS:Sham stimulation
sham tDCS+iTBS:Sham tDCS+iTBS
Sponsors
The First Affiliated Hospital with Nanjing Medical University(Jiangsu Provincial People's Hospital)
Eligibility
Sex/Gender
All
Age
55 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Age 55-75 years old (inclusive); 2. Right-handed, verified by Edinburgh handedness Scale; 3. More than one cognitive domain was impaired, and the most significant and earliest was episodic memory; 4. The remainder had to meet one of three criteria: first, scores on two neuropsychological measures below 1.0 standard deviation (SD) in at least one cognitive domain (memory, language, or executive function); Second, a score of less than 1.0SD on a neuropsychological measure in each of the three cognitive domains (memory, language, or executive functioning) was observed. Third, the functional activity questionnaire score was >=9. 5. The cut-off values based on SD used in this study referred to the published studies on Chinese population and were adjusted for education level and age.
Exclusion criteria
Exclusion criteria: In the trial, if a subject meets any of the following criteria, he or she should withdraw from this clinical trial: 1.Meet the diagnostic criteria for vascular dementia established by the National Institute of Neurological Disorders and Stroke and the Swiss Association for Neuroscience Research International (NINDS-AIREN); 2.Modified Hachinski ischemia Scale score >4; 3.Unable to cooperate with cognitive function examination (including blind, deaf, severe language impairment, etc.); 4.Drug or alcohol dependence in the past 6 months; 5.Participating in other clinical research; 6.Serious cardiovascular disease, cerebrovascular disease, liver disease, kidney disease and mental disorders; 7.History of epilepsy, idiopathic epilepsy in first-degree relatives and use of epileptogenic drugs; 8.Patients with skull defect at TMS stimulation site; 9.Implants such as cardiac pacemaker, artificial metal heart valve, insulin pump, drug therapy pump, aneurysm clip (except non-paramagnetic such as titanium alloy); 10.Claustrophobic, unable to cooperate with MRI examination; 11.Use of drugs that affect cortical excitability such as antidepressants, anxiolytics, and sedatives within 3 months before or during cognitive assessment; Use of drugs that affect cognitive function or participate in other clinical drug trials; 12.Geriatric Depression Scale score >=6.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Episodic memory;N-back;Functional NIR imaging index;Functional magenetic resonance imaging index;Peripheral blood indicators (whole blood transcriptome, neurodegeneration markers, neurotrophic factors, synaptic proteins); | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall cognitive function;Mental State;Animal Fluency ;Shape trail making ;Boston Naming ;Symbol Digital Modalities; | — |
Countries
China
Contacts
Public ContactYing Shen
The First Affiliated Hospital with Nanjing Medical University(Jiangsu Provincial People's Hospital)
Outcome results
None listed